背景:经皮球囊压迫(PBC)是一种有效的,低成本,原发性三叉神经痛(TN)的简单治疗。然而,PBC的疗效较差,对TN的第三分支(V3)没有更好的解决方案。
方法:回顾性分析52例三叉神经痛患者的临床资料。在巴罗神经研究所(BNI-N)通过面部麻木评估患者的术后麻木。主要观察结果是,在术后即刻,V3的麻木发生率高于其他两个分支,或三个分支的麻木发生率相同。
结果:梨形球囊组在术后第一天(T1)的疗效值,第一个月(T2),在第三个月(T3),第六个月(T4)为96.7%,93.3%,93.3%,90%,分别,1例(3.3%)复发。囊外胶囊组的疗效值始终为95.5%,术后6个月内无复发患者。在术后即刻,梨形球囊组V3的有效压缩率为43.3%,囊外胶囊组为86.4%(P=0.020)。在六个月的随访中,囊外胶囊组V3的有效压缩率高于梨形球囊组。
结论:囊外胶囊的铆接结构可以有效地压缩V3,因此以球囊形状为囊外胶囊的PBC是一种新的,有效,和TNV3的安全治疗选择。
背景:ClinicalTrials.govChiCTR2300067313。
BACKGROUND: Percutaneous balloon compression (PBC) is an effective, low-cost, and simple treatment for primary trigeminal neuralgia (TN). However, PBC has poor efficacy and no better solution for the third branch (V3) of TN.
METHODS: Clinical data of 52 patients with trigeminal neuralgia treated with PBC were retrospectively analyzed. Postoperative numbness of the patient was evaluated by facial numbness at the Barrow Neurological Institute (BNI-N). The main observation was the incidence of higher numbness in the V3 than in the other two branches or equally strong numbness in the three branches in the immediate postoperative period.
RESULTS: The efficacy values in the pear-shaped balloon group at the first postoperative day (T1), the first month (T2), in the third month (T3), and the sixth month (T4) were 96.7%, 93.3%, 93.3%, and 90%, respectively, and 1 patient (3.3%) had recurrence. The efficacy value for the extracapsular capsule group was 95.5% at all times and there were no patients with recurrence within 6 months after surgery. In the immediate postoperative period, the effective compression rate of V3 in the pear-shaped balloon group was 43.3%, and 86.4% in the extracapsular capsule group (P = 0.020). At six months of follow-up, the effective compression rate of V3 was higher in the extracapsular capsule group than in the pear-shaped balloon group.
CONCLUSIONS: The riveted structure of the extracapsular capsule can effectively compress V3, thus performing PBC with a balloon shaped as an extracapsular capsule is a new, effective, and safe treatment option for TN V3.
BACKGROUND: ClinicalTrials.gov ChiCTR2300067313.